Brought to you by 
Orion and Hospira grant Sandoz the right to sell a Precedex generic
29 Jan 2014
Executive Summary
Hospira Inc. and Orion Corp. settled patent litigation and granted Novartis AG’s Sandoz the right to launch in the US a generic version of Precedex (dexmedetomidine) on December 26, 2014, or sooner under certain circumstances. The legal proceeding pertained to Hospira’s US Patent No. 6,716,867 and Orion’s US Patent No. 4,910,214. Precedex is approved for the sedation of intubated and mechanically ventilated patients for up to 24 hours in the intensive care unit.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Orion and Hospira grant Sandoz the right to sell a Precedex generic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice